Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

278
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
278
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

193
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
193
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

5.2K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.2K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

2.5K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.5K
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

2.2K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.2K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

2.9K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modeling the Sensitivity of Large-Scale Virtual Screening to Scoring Function Accuracy, Artifacts, and Library Composition.

Journal of chemical information and modeling·2026
Same author

Cannabinoid (CB) 1 receptor antagonists block fentanyl conditioned place preference but not fentanyl antinociception.

Drug and alcohol dependence·2026
Same author

Library Docking for Cannabinoid-2 Receptor Ligands.

Journal of medicinal chemistry·2026
Same author

First Structure-Activity-Relationship Study of Potent G2A Antagonists.

Journal of medicinal chemistry·2026
Same author

The Selectivity Implications of Docking Libraries with Greater and Lesser Similarities to Bio-like Molecules.

Journal of medicinal chemistry·2026
Same author

Drug-Induced Phospholipidosis as an Artifact in Antiviral Drug Repurposing.

ACS omega·2026

Related Experiment Video

Updated: Jul 4, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K

Large library docking for cannabinoid-1 receptor agonists with reduced side effects.

Tia A Tummino, Christos Iliopoulos-Tsoutsouvas, Joao M Braz

    Biorxiv : the Preprint Server for Biology
    |February 8, 2024
    PubMed
    Summary

    Researchers discovered novel cannabinoid chemotypes by docking millions of molecules to find new cannabinoid-1 receptor (CB1R) agonists. This led to a potent new agonist with strong analgesic effects and a wide therapeutic window, suggesting potential for safer pain treatments.

    More Related Videos

    Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
    05:25

    Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

    Published on: December 29, 2021

    2.6K
    Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
    07:16

    Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

    Published on: August 16, 2018

    13.6K

    Related Experiment Videos

    Last Updated: Jul 4, 2025

    Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
    10:33

    Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

    Published on: October 26, 2015

    11.3K
    Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
    05:25

    Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

    Published on: December 29, 2021

    2.6K
    Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
    07:16

    Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

    Published on: August 16, 2018

    13.6K

    Area of Science:

    • Medicinal Chemistry
    • Neuroscience
    • Structural Biology

    Background:

    • The cannabinoid-1 receptor (CB1R) is a key target for pain therapeutics.
    • Existing CB1R agonists often exhibit dose-limiting side effects, hindering clinical application.
    • Discovery of novel chemotypes is crucial for developing safer and more effective CB1R-targeting drugs.

    Conclusions:

    • Novel cannabinoid chemotypes can be effectively discovered using large-scale docking approaches.
    • The developed CB1R agonist ('4042) exhibits a promising profile for pain management, potentially separating analgesia from common side effects.
    • These findings support the continued development of novel cannabinoids for therapeutic applications in pain relief.